论文部分内容阅读
目的探讨ＭＤＲ１基因表达产物Ｐ－糖蛋白（Ｐ－ｇｐ）在非小细胞肺癌中的表达水平及其临床意义。方法采用免疫组织化学标记链亲和素－生物素法检测１２６例非小细胞肺癌标本中Ｐ－ｇｐ的表达。结果（１）Ｐ－ｇｐ总的阳性表达率为５６．３％（７１／１２６）；（２）腺癌与鳞癌之间，鳞癌与腺鳞癌之间Ｐ－ｇｐ的表达阳性率无显著差异（Ｐ＞０．０５），但腺鳞癌Ｐ－ｇｐ的阳性表达率高于腺癌（Ｐ＜０．０５）；（３）Ｐ－ｇｐ的表达与性别、年龄、肿瘤生长部位、病理分期及是否伴有淋巴结转移无关。结论Ｐ－ｇｐ在非小细胞肺癌中有较高的阳性表达率，且与病理类型有一定关系，提示在非小细胞肺癌尤其是Ｐ－ｇｐ高度表达类型肺癌的化疗中，应重视Ｐ－ｇｐ介导的多药耐药性。
Objective To investigate the expression and clinical significance of P-glycoprotein (P-gp), an MDR1 gene expression product, in non-small cell lung cancer. Methods The expression of P-gp in 126 specimens of non-small cell lung cancer was detected by immunohistochemistry with streptavidin-biotin method. Results (1) The total positive expression rate of P-gp was 56.3% (71/126). (2) The positive rate of P-gp expression between adenocarcinoma and squamous cell carcinoma was not between squamous cell carcinoma and adenosquamous carcinoma. Significant difference (P>0.05), but the positive expression rate of P-gp in adenosquamous carcinoma was higher than that in adenocarcinoma (P<0.05); (3) Expression of P-gp and sex, age, site of tumor growth, Pathological stage and whether associated with lymph node metastasis. Conclusion P-gp has a high positive rate in non-small cell lung cancer, and has a certain relationship with pathological types, suggesting that P-gp should be emphasized in the chemotherapy of non-small cell lung cancer, especially P-gp highly expressed type lung cancer. Mediated multidrug resistance.